Celltrion, Inc.
Financials
Valuation Metrics
Celltrion, Inc.'s Market Cap is ₩44.6T. At end of 2025 it was ₩40.0T. Ranked #11 of 2,405 in KR market (top 0.5%), #11 of 778 on KOSPI (top 1%), #2 of 231 in Pharmaceuticals, Biotechnology & Life Sciences (top 0.9%) by Market Cap.
Investment Metrics(as of 2026-11-02)
| Metric | Value | Rank |
|---|---|---|
| Size | ||
| Market Cap | 44.63T KRW | KR#11/2,405 Sec#2/231 |
| Revenue | 4.90T KRW | KR#132/2,405 Sec#1/231 |
| Net Income | 1.58T KRW | KR#33/2,405 Sec#2/231 |
| Total Assets | 22.33T KRW | KR#72/2,405 Sec#1/231 |
| Net Assets | 17.35T KRW | KR#34/2,405 Sec#1/231 |
| Employees | 2,901 | KR#106/2,405 Sec#2/231 |
| Value | ||
| P/E | 28.23x | KR#1,307/2,405 Sec#81/231 |
| P/B | 2.57x | KR#2,085/2,405 Sec#162/231 |
| PEG | 0.13x | KR#479/2,405 Sec#26/231 |
| P/S | 9.11x | KR#2,265/2,405 Sec#164/231 |
| EV/EBITDA | 30.48x | KR#1,226/2,405 Sec#77/231 |
| FCF Yield | 1.45% | KR#1,104/2,405 Sec#76/231 |
| Profitability | ||
| ROE | 9.11% | KR#689/2,405 Sec#48/231 |
| ROA | 7.08% | KR#507/2,405 Sec#39/231 |
| Op. Margin | 31.65% | KR#52/2,405 Sec#12/231 |
| Revenue Growth | 30.64% | KR#380/2,405 Sec#38/231 |
| Earnings Growth | 222.61% | KR#225/2,405 Sec#12/231 |
| Financial Health | ||
| Debt Ratio | 28.71% | KR#552/2,405 Sec#62/231 |
| Total Debt | 3.74T KRW | KR#85/2,405 Sec#1/231 |
| FCF | 646.05B KRW | KR#48/2,405 Sec#2/231 |
| Cash | 1.12T KRW | KR#92/2,405 Sec#1/231 |
| Net Debt/EBITDA | 1.69x | KR#809/2,405 Sec#57/231 |
| Dividend | ||
| Div. Yield | 0.37% | KR#1,308/2,405 Sec#83/231 |
| Div. Growth | 0.00% | KR—/2,405 Sec—/231 |
| Performance | ||
| 1Y Return | 14.89% | KR#377/2,405 Sec#22/231 |
| 1M Return | 5.31% | KR#164/2,405 Sec#16/231 |
| From 52W High | -19.62% | KR#181/2,405 Sec#9/231 |
| 1Y MDD | -32.70% | KR#319/2,405 Sec#23/231 |
| Trading | ||
| Volume | 295,041 shares | KR#263/2,405 Sec#18/231 |
| Trading Value | 56.94B KRW | KR#43/2,405 Sec#1/231 |
| Foreign Own. | 25.25% | KR#164/2,405 Sec#5/231 |
| Per Share | ||
| EPS | 6,813 KRW | KR#167/2,405 Sec#8/231 |
| BPS | 74,772 KRW | KR#185/2,405 Sec#11/231 |
Company Info
Celltrion, established in 1991, completed its KOSDAQ listing in 2005 and transferred to the Securities Market in 2018, building a unified corporate structure through the absorption merger of Celltrion Healthcare in 2023. It develops, produces, and sells antibody drugs using biotechnology and animal cell mass culture technology, possessing an 11-product portfolio. The company is strengthening its next-generation antibody drug pipeline through alliances and investments with global biotech companies. Celltrion is headquartered in Yeonsu-gu, Incheon Metropolitan City.